Talaris Therapeutics Inc.

11/30/2021 | Press release | Distributed by Public on 11/30/2021 06:02

Talaris Therapeutics Announces Initiation of Phase 2 Clinical Trial of FCR001 in Individuals with a Severe Form of Scleroderma